



## KIDNEY MEASURE SPECIFICATIONS

### Cancer Programs Practice Profile Reports (CP<sup>3</sup>R)

#### Introduction

The Commission on Cancer's (CoC) National Cancer Data Base (NCDB) staff has undertaken an effort to improve the transparency with which the measures in the CP<sup>3</sup>R and RQRS reporting systems are calculated. To this end, for each measure, supporting information, three tables and a flow-diagram are provided:

- The measure type, clinical rationale and references are provided.
- The *Measure Item List* table provides each cancer registry data item used in the assessment of the indicated measure. This includes the FORDS data item name, the North American Association of Central Cancer Registry (NAACCR) item number and a brief description of each item.
- The *Case Eligibility Criteria* table itemizes the steps taken to determine whether cases belong in the measure denominator for cases diagnosed 2010 and later. Each condition is described and is accompanied by the data item and code values used in the assessment.
- The *Numerator Criteria* table illustrates how cases are assessed to determine whether they qualify for the numerator of the measure, in other words are concordant for the standard of care.
- A **flow-diagram** is provided to illustrate the steps through which cases pass as they are evaluated for the indicated measure. The number appearing in each flow-diagram element corresponds to the assessment criteria appearing in the *Case Eligibility Criteria* and *Numerator Criteria* tables.

#### Measure Descriptions

This document provides specifications for the following measures:

Measure	Measure Abbreviation	Measure Type
Pediatric Measure: At least 1 regional lymph node is removed and pathologically examined for primarily resected unilateral nephroblastoma	PD1RLN	Surveillance

Note: Newly adopted measures will be integrated into CP<sup>3</sup>R prior to their release in RQRS.

#### Measure Type

There are several types of measures approved by the CoC. Evidence-based measures or **accountability** measures promote improvements in care delivery and are the highest standard for measurement. These measures demonstrate provider accountability, influence payment for services and promote transparency. The **quality improvement** measure function is to monitor the need for quality improvement or remediation. Generally, these measures are for individual program use. **Surveillance** measures are used to identify the status quo, generate information for decision making, and/or to monitor patterns and trends of care. The following Table summarizes the purposes and use of these measures:

<b>Measure Type</b>	<b>Measure definition and use</b>
<b>Accountability</b>	High level of evidence supports the measure, including multiple randomized control trials. These measures can be used for such purposes as public reporting, payment incentive programs, and the selection of providers by consumers, health plans, or purchasers.
<b>Quality Improvement</b>	Evidence from experimental studies, not randomized control trials supports the measure. These are intended for internal monitoring of performance within an organization.
<b>Surveillance</b>	Limited evidence exist that supports the measure or the measure is used for informative purposes to accredited programs. These measures can be used for to identify the status quo as well as monitor patterns and trends of care in order to guide decision-making and resource allocation.



**PD1RLN - Pediatric Measure: At least 1 regional lymph node is removed and pathologically examined for primarily resected unilateral nephroblastoma**

Measure type: Surveillance

<b>Measure Item List</b>		
<b>FORDS Data Item</b>	<b>NAACCR #</b>	<b>Description</b>
Primary Site	400	Organ of origin of the cancer
Sex	220	Sex of patient
Age at Diagnosis	230	Age of patient at diagnosis
Sequence Number	560	Sequence of malignant and nonmalignant neoplasms over the lifetime
Histology	522	Microscopic or cellular anatomy of the cancer
Behavior Code	523	Neoplastic behavior of the cancer
Class of Case	610	Indicates the reporting facility's role in managing the cancer
Laterality	410	Identifies the side of a paired organ or the side of the body on which the tumor originated
Surgical Procedure of the Primary Site at this facility	670	Surgical procedure of the primary site performed at this facility
Date of Most Definitive Surgical Resection of the Primary Site	3170	Date of Most Definitive Surgical Resection of the Primary Site performed as part of the first course of treatment
Chemotherapy	1390	The type of chemotherapy administered as first course of treatment at any facility
Date Chemotherapy Started	1220	Date of the initiation of chemotherapy that is part of the first course of treatment
Regional Lymph Nodes Examined	830	Total number of regional lymph nodes that were removed and examined
Regional Lymph Nodes Positive	820	Total number of regional lymph nodes examined and found to contain metastases

The PD1RLN measure applies to cases diagnosed starting in 2010.

<b>Case Eligibility Criteria</b>			
<b>Diagram Reference</b>	<b>Assessment</b>	<b>FORDS Item</b>	<b>FORDS Codes</b>
1	Primary Site - Kidney	Primary Site	C64.9
2	Male or female	Sex	1, 2
3	Pediatric patient under the age of 18 at diagnosis	Age at Diagnosis	0 - 17
4	First or only cancer diagnosis	Sequence Number	00, 01
5	Nephroblastoma	Histology	8960
6	Invasive tumors	Behavior Code	3
7	All or part of the first course of treatment was performed at the reporting facility	Class of Case	10, 11, 12, 13, 14, 20, 21, or 22
8	Right only, left only, or unknown/unspecified with only one side involved	Laterality	1, 2, 3
9	Nephrectomy performed at this facility	Surgical Procedure of the Primary Site at this facility	30, 40, 50, 70, 80
10	Exclude cases with chemotherapy before surgery	Chemotherapy	<b>Exclude if:</b> Chemotherapy = 01, 02, 03 <b>AND</b> Date Chemotherapy Started < Date of Most Definitive Surgical Resection of the Primary Site
		Date Chemotherapy Started	
		Date of Most Definitive Surgical Resection of the Primary Site	

Numerator Criteria			
Diagram Reference	Assessment	FORDS Item	FORDS Codes
11	At least 1 regional lymph nodes is removed and pathologically examined	Regional Lymph Nodes Examined	(Regional Lymph Nodes Examined 01 - 90 <i>and</i> Regional Lymph Nodes Examined $\geq$ Regional Lymph Nodes Positive) <b>OR</b> Regional Lymph Nodes Examined 96, 97, 98 <i>(Cases with no lymph nodes examined 00, 95 are non-compliant)</i>
		Regional Lymph Nodes Positive	

Note:

1. PD1RLN is a new measure introduced in June 2017 into CP<sup>3</sup>R



**PD1RLN - Pediatric Measure: At least 1 regional lymph node is removed and pathologically examined for primarily resected unilateral nephroblastoma**

